Genetic test research leads to new warfarin dosing model

August 23, 2007

New research published in the Sept. 1 issue of Blood involving the use of genetic testing to predict a therapeutic warfarin dose has led to the development of a new dosing model for the drug.

New research published in the Sept. 1 issue of Blood involving the use of genetic testing to predict a therapeutic warfarin dose has led to the development of a new dosing model for the drug. Sponsored by NIH, the study combined use of the standard INR with genetic testing for variations in both the CYP2C9 and VKORC1 genes. The patients were assigned initial doses of warfarin based on clinical factors and their genotype and were then followed for several weeks. The researchers developed a dosing equation that estimated the therapeutic warfarin dose and found that the two genes were important factors in predicting response to the drug. The new dosing model has been made publicly available at